Seagen Talks Up 24% Growth, Not About Speculated Merck Buyout

Daiichi Arbitration Is Another Wildcard

The Seattle-based biotech reported a 24% increase in product sales in the second quarter amid speculation that Merck is about to acquire the company.

Like Merck before it, Seagen kept quiet about a speculated buyout deal between the two companies • Source: Shutterstock

Seagen Inc. disappointed most observers by not talking about the potential buyout of the company by Merck & Co., Inc. during its 28 July earnings report, keeping quiet as Merck did itself in its earnings release the same day. But the Seattle-based company did highlight fundamentals that will be a factor in a possible acquisition, including strong sales growth for its key products and an update on another closely watched situation, its legal dispute with Daiichi Sankyo Co., Ltd.

The company reported total revenue of $498m and product sales of $431.7m for the second quarter, a 24% increase over...

More from Earnings

Cipla CEO On Tariff Threat: ‘We Have One Of The Most Well Diversified Models’

 

Cipla's leadership fields shareholder queries on the specter of US tariffs and also outlines how the firm is nurturing the business for the future in areas like mRNA and point-of-care diagnostics, while building on its strength in the respiratory space.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

J&J Delivers In Q2 Despite Stelara Drop, Raising Guidance

 

Stelara revenues declined 42.7% in the quarter due to biosimilars, but innovative medicines grew 4.9%, surpassing $15bn for the quarter. Although pharma tariffs could be coming, the firm said the impact continues to be hard to predict.

Stock Watch: Pharma Financial Forecasts Cannot Withstand Headwinds Forever

 
• By 

Pharma company financial guidance emerged largely unscathed from a first quarter punctured by a weakening US dollar and threats of import tariffs on drugs. With other pressures either already evident or on the horizon, guidance revisions may be unavoidable.

More from Business